You are here

Positive Phase III Results for Linalidomide (Revlimid) in Asymptomatic Myeloma

Combo therapy with dexamethasone improves 3-year survival (August 1)

Positive results have been reported from a phase III study that evaluated lenalidomide (Revlimid, Celgene) in combination with dexamethasone followed by lenalidomide maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma. The new findings were published in the August 1 issue of the New England Journal of Medicine.

Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10%-per-year risk of progression to symptomatic disease during the first 5 years.

After a median follow-up period of 40 months, the median time to progression to symptomatic disease — the study’s primary endpoint —was significantly longer in the treatment group compared with the observation group (not reached vs. 21 months, respectively; hazard ratio [HR] = 0.18; P P = 0.03). A partial response was observed in 79% of the patients in the treatment group during induction, and in 90% during the maintenance phase.

The most common grade 3 adverse events (AEs) in the treatment arm included infection (6%), asthenia (6%), neutropenia (5%), and rash (3%). No grade 4 AEs were reported. One patient had a grade 5 AE, reported as a respiratory infection.

Sources: Celgene; August 1, 2013; and NEJM; August 1, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs